Similar articles

• Response to philanthropic support of HPV vaccination efforts.

  Harper DM, Wall J, Verdenius I, Harris GD. Harper DM, et al. Prev Med. 2015 Jul;76:127-8. doi: 10.1016/j.ypmed.2014.12.042. Epub 2015 Feb 2. Prev Med. 2015. PMID: 25657170 No abstract available.
• The influence of free quadrivalent human papillomavirus vaccine (HPV4) on the timely completion of the three dose series.

  Harper DM, Verdenius I, Harris GD, Barnett AL, Rosemergey BE, Arey AM, Wall J, Malnar GJ. Harper DM, et al. Prev Med. 2014 Apr;61:20-5. doi: 10.1016/j.ypmed.2014.01.007. Epub 2014 Jan 15. Prev Med. 2014. PMID: 24440159
• Acceptance and compliance with postpartum human papillomavirus vaccination.

  Wright JD, Govindappagari S, Pawar N, Cleary K, Burke WM, Devine PC, Lu YS, Tsai WY, Lewin SN, Herzog TJ. Wright JD, et al. Obstet Gynecol. 2012 Oct;120(4):771-82. doi: 10.1097/AOG.0b013e31826afb56. Obstet Gynecol. 2012. PMID: 22996094 Clinical Trial.
• Safety of HPV vaccines in the age of nonavalent vaccination.

  Quattrone F, Canale A, Filippetti E, Tulipani A, Porretta A, Lopalco PL. Quattrone F, et al. Minerva Pediatr. 2018 Feb;70(1):59-66. doi: 10.23736/S0026-4946.17.05147-7. Minerva Pediatr. 2018. PMID: 29363293 Review.
• Spotlight on quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine(Gardasil®) in the prevention of premalignant genital lesions, genital cancer, and genital warts in women.

  McCormack PL, Joura EA. McCormack PL, et al. BioDrugs. 2011 Oct 1;25(5):339-43. doi: 10.2165/11205060-000000000-00000. BioDrugs. 2011. PMID: 21942919 Review.